glp-1 patient medications and weight loss: Helping patients navigate beyond the trends Patients' Use GLP-1 Drugs for

Ania Jastreboff, an obesity medicine physician scientist at Yale University School of Medicine/Yale School of Medicine, co-Director of the Yale Center for Weight Management and the lead author on the phase 2 study, said that the results were striking and concluded that Retatrutide holds promise for substantial weight reduction in adults with obesity over a 48-week period

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

Frustrated with diets that don't deliver

Their work can further research into aging, cancer, Alzheimer's, fertility, degenerative diseases and more

157 These differences necessitate a re-examination of clinical experiences in adults for application to children

Researchers examined reports submitted between the first quarter of 2022 and the third quarter of 2023, a period when GLP-1 prescriptions surged